Literature DB >> 9395746

Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding.

G D'Amico1, A Luca.   

Abstract

Promoting the development of oesophageal varices and ascites, portal hypertension dominates the clinical course of cirrhosis. Varices appear in patients with portal pressure gradient above 10 mmHg and enlarge in 10-20% within 1-2 years of their detection. Bleeding occurs in patients with portal pressure gradient above 12 mmHg when the wall tension causes the rupture of varices, with an incidence of about 10% per year. Indicators of bleeding risk are portal pressure gradient, variceal pressure, large varices and liver dysfunction. Mortality per bleeding episode is 30-50%. Among survivors 60% will rebleed and 30% will die in the following year. The risk of rebleeding decreases in patients with spontaneous or treatment induced reduction of portal pressure gradient or variceal pressure. Ascites develops in almost all patients along the course of the disease. Median survival after its appearance is less than 2 years. Less than 5% of cirrhotic patients die without ascites or without a previous bleeding. Thus portal hypertension is a major determinant of survival in cirrhosis.

Entities:  

Mesh:

Year:  1997        PMID: 9395746     DOI: 10.1016/s0950-3528(97)90038-5

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  41 in total

1.  Post-gastrectomy spleen enlargement and esophageal varices: distal vs total gastrectomy.

Authors:  Takatsugu Oida; Kenji Mimatsu; Hisao Kano; Atsushi Kawasaki; Youichi Kuboi; Nobutada Fukino; Sadao Amano
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Percutaneous transhepatic embolization of gastroesophageal varices combined with partial splenic embolization for the treatment of variceal bleeding and hypersplenism.

Authors:  Wei-Dong Gong; Ke Xue; Yuan-Kui Chu; Qing Wang; Wei Yang; Hui Quan; Peng Yang; Zhi-Min Wang; Zhi-Qun Wu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Adjusted blood requirement index as indicator of failure to control acute variceal bleeding.

Authors:  Marko Duvnjak; Neven Barsić; Vedran Tomasić; Lucija Virović Jukić; Ivan Lerotić; Tajana Pavić
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

Review 4.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

5.  Independent factors associated with recurrent bleeding in cirrhotic patients with esophageal variceal hemorrhage.

Authors:  Shou-Wu Lee; Teng-Yu Lee; Chi-Sen Chang
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

Review 6.  Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review.

Authors:  Enrico Maria Zardi; Francesco Maria Di Matteo; Claudio Maurizio Pacella; Arun J Sanyal
Journal:  Ann Med       Date:  2013-12-16       Impact factor: 4.709

7.  Proton pump inhibitor administration delays rebleeding after endoscopic gastric variceal obturation.

Authors:  Won Seok Jang; Hyun Phil Shin; Joung Il Lee; Kwang Ro Joo; Jae Myung Cha; Jung Won Jeon; Jun Uk Lim
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Improving prognosis following a first variceal haemorrhage over four decades.

Authors:  P A McCormick; C O'Keefe
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

9.  Right liver lobe/albumin ratio: contribution to non-invasive assessment of portal hypertension.

Authors:  Tamara Alempijevic; Vladislava Bulat; Srdjan Djuranovic; Nada Kovacevic; Rada Jesic; Dragan Tomic; Slobodan Krstic; Miodrag Krstic
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

10.  Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis.

Authors:  E Giannini; F Botta; P Borro; D Risso; P Romagnoli; A Fasoli; M R Mele; E Testa; C Mansi; V Savarino; R Testa
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.